Quote:

---

I am totally shell shocked beyond imagination that shares of CYDY are not up around $2.00/share with the announcement of IRB approval of the basket trial. If this was another budding bio pharma on the NYSE or the Nasdaq, it would have blown the doors off of it's stock.

---

I think most of us agree with you. Perhaps we are a product of our own success in a way. We are still very early in the development of all of the indications, but I would propose that the very fact that we have so many potential indications, and so many positive things going on, that the average investor is desensitized to a degree.

I often think back to the call wherein NP announced the finalization of the Vyera deal. Moments earlier he mentioned that we are starting to study leronlimab as a treatment for Multiple Sclerosis. My initial reaction was "Meh, just another indication." But I caught myself, because that is a HUGE deal for a lot of people. We dont even talk about MS because of all of the other things going on.